Entering text into the input field will update the search result below

Jefferies says familiar names will be the strongest biotechs this year

  • Barron's reports that Jefferies believes "only the strong (biotechs) will survive" this year. Despite strong underlying science, a more receptive regulatory environment and continued pricing power for innovative products, headwinds remain. The inability to aggressively hike prices for core franchises will place more of a premium on innovation and M&A to drive growth. Key picks:
  • Large cap: Celgene (CELG +0.2%), Gilead Sciences (GILD -0.5%).
  • Mid cap: Alkermes (ALKS -0.9%), Vertex Pharmaceuticals (VRTX +2.8%).
  • Small cap: Aevi Genomic Medicine (GNMX -0.2%), Alder BioPharmaceuticals (ALDR +2.2%), AMAG Pharmaceuticals (AMAG +3.5%), DBV Technologies (DBVT +1.1%), Immunomedics (IMMU), Ignyta (RXDX +10.8%), Karyopharm Therapeutics (KPTI +2.6%), Ra Pharmaceuticals (RARX +4.2%), TherapeuticsMD (TXMD -0.6%), Xenon Pharmaceuticals (XENE -1.9%).

Recommended For You

Related Stocks

SymbolLast Price% Chg
CELG--
Celgene Corporation
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.